Robert Halsted
Internal Medicine · Washington, MONPI 1447286380
Payments from drug & device makers
Across 75 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$375
- Johnson & Johnson$197
- Janssen Scientific Affairs, LLC$107
- Novo Nordisk$73
- Boehringer Ingelheim$69
- Amgen$65
- plus $327 from 15 others
What the payments were for
- Food & beverage$1,19699%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $375 |
| Johnson & Johnson | 16 | $197 |
| Janssen Scientific Affairs, LLC | 1 | $107 |
| Novo Nordisk | 6 | $73 |
| Boehringer Ingelheim | 5 | $69 |
| Amgen | 5 | $65 |
| AstraZeneca | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $30 |
| Merck | 2 | $28 |
| Novartis | 2 | $24 |
| Nevro Corp. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Electromed, Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
| Bayer | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
| Pfizer | 1 | $12 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$107
How this compares
$1,212 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $11,372 |
| Sevelamer Carbonate | 11 | $1,349 |
| Atorvastatin Calcium | 90 | $1,041 |
| Omeprazole | 46 | $809 |
| ClopidogrelClopidogrel Bisulfate | 32 | $535 |
| Amlodipine Besylate | 49 | $503 |
| Tamsulosin Hcl | 24 | $451 |
| Finasteride | 19 | $410 |
| Celecoxib | 22 | $355 |
| Donepezil Hcl | 26 | $343 |
| Citalopram HbrCitalopram Hydrobromide | 25 | $245 |
| Lisinopril | 19 | $161 |
| Levothyroxine Sodium | 21 | $155 |
| Furosemide | 22 | $142 |
| Losartan Potassium | 24 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $11,37213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Washington
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.